Atherixen (COVID-19 coronavirus drug)

2022: Start of Sales

On September 12, 2022, the Russian pharmaceutical company Valenta Pharm (Domestic Medicines) announced the start of sales in the Russian Federation of the drug for the treatment of coronavirus (COVID-19) infection Atheriksen. The medicine is intended for adults.

According to the developers, the drug helps the body fight virus-induced inflammation and thereby minimize the risk of developing complications of COVID-19. The company noted that the conducted preclinical and clinical studies demonstrated the high effectiveness of Atheriksen and confirmed that the drug has a low level of toxicity and a high safety profile, TASS reports with reference to the press service of Valenta Farm.

Atheriksen

It is noted that the drug is intended for the treatment of coronavirus infection and in the future for the treatment of other acute respiratory viral infections, including influenza. Atheriksen will be produced primarily to meet the needs of Russian patients in the fight against the COVID-19 coronavirus pandemic. In the future, it is planned to supply the drug to the countries of Southeast Asia.

It is specified that Atheriksen by mid-September 2022 was registered only for the treatment of adult patients with mild COVID-19. According to studies, the drug reduces the number of hospitalizations in outpatients with coronavirus by 80%.

The start of mass production was originally planned for the end of the second - beginning of the third quarter of 2022. Thus, the manufacturer managed to withstand the planned deadlines, and from mid-September 2022, the drug can be purchased in Russian pharmacies. For example, on the Аптека.ру website, the medicine is available at a price of 3672 rubles per package with 28 tablets.^[1]

Notes